 BOSTON, May 21, 2021 GLOBE NEWSWIRE -- Aprea Therapeutics, Inc. Nasdaq: APRE, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare Orphan Disease Summit on Friday, May 21, 2021 at 3:45 p.m. ET. 